Primjena ciklodekstrina u razvoju farmaceutskih oblika za primjenu antitumorskih lijekova

Professional paper - Review paper

• Author: Martina Nikolin
• Author: Mario Jug
• Author's institution: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmaceutical technology)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract (english)

Cyclodextrins (CDs) are excipients able to form inclusion complexes
with sterically compatible lipophilic endogenous molecules
and drugs, increasing their solubility and chemical stability. Enhanced biocompatibility
and the potential to form nanostructures give CDs an advantage
over other commercially available excipients. CDs appear as attractive carriers
for antitumor drugs, which often show limited aqueous solubility and chemical
stability. Therefore, CD may provide the development of new dosage forms and
delivery systems of antitumor drugs with improved bioavailability, reduced toxicity
and enhanced therapeutical efficiency. In addition, the interactions of CDs
with endogenous molecules may act synergistically with antitumor drugs in
cancer treatment. Further functionalization of CDs by attaching the ligands specific
for receptors typical for tumour cells may provide active tumor targeting of
the included cytostatic drugs, additionally enhancing the effectiveness and safety
of cancer therapy.

• Keywords (croatian): ciklodekstrini; citostatici; farmaceutski oblici; tumori; antitumorski lijekovi
• Language: croatian
• Publication type: Professional paper - Review paper
• Publication status: Published
• Peer review: Peer review - domestic
• Publication version: Published version
• Journal title: Farmaceutski glasnik
• Numbering: vol. 79, no. 1-2, pp. 1-20
• p-ISSN: 0014-8202
• URN:NBN: urn:nbn:hr:163:385656
• Publication: 2023
• Type of resource: Text
• Access conditions: Open access
• Created on: 2023-03-14 14:08:17